Doxorubicin-loaded micelles in tumor cell-specific chemotherapy
Environmental Research · 2023-06 · 227 · 115722
DOI: 10.1016/j.envres.2023.115722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Environmental Research, 2023-06. Verfasst von Yasir Qasim Almajidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Baghdad College of Medical Sciences, Baghdad, Iraq. Hauptthemen laut MEDLINE: Micelles, Doxorubicin. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 279 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Nanomedicine is a field that combines biology and engineering to improve disease treatment, particularly in cancer therapy. One of the promising techniques utilized in this area is the use of micelles, which are nanoscale delivery systems that are known for their simple preparation, high biocompatibility, small particle size, and the ability to be functionalized. A commonly employed chemotherapy drug, Doxorubicin (DOX), is an effective inhibitor of topoisomerase II that prevents DNA replication in cancer cells. However, its efficacy is frequently limited by resistance resulting from various factors, including increased activity of drug efflux transporters, heightened oncogenic factors, and lack of targeted delivery. This review aims to highlight the potential of micelles as new nanocarriers for delivering DOX and to examine the challenges involved with employing chemotherapy to treat cancer. Micelles that respond to changes in pH, redox, and light are known as stimuli-responsive micelles, which can improve the targeted delivery of DOX and its cytotoxicity by facilitating its uptake in tumor cells. Additionally, micelles can be utilized to administer a combination of DOX and other drugs and genes to overcome drug resistance mechanisms and improve tumor suppression. Furthermore, micelles can be used in phototherapy, both photodynamic and photothermal, to promote cell death and increase DOX sensitivity in human cancers. Finally, the alteration of micelle surfaces with ligands can further enhance their targeted delivery for cancer suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Baghdad College of Medical Sciences, Baghdad, Iraq.
- Department of Dentistry, Kut University College, Kut, Wasit, 52001, Iraq; Medical Laboratory Techniques Department, Al-Farahidi University, Baghdad, 10022, Iraq.
- College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
- Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq. Electronic address: abedalazeem799@gmail.com.
- National University of Science and Technology, Dhi Qar, Iraq.
- Azogues Campus Nursing Career, Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Ecuador; Epidemiology and Biostatistics Research Group, CES University, Colomb…
Zitieren
APA
Almajidi, Y. Q., Kadhim, M. M., Alsaikhan, F., Turki Jalil, A., Hassan Sayyid, N., Alexis Ramírez-Coronel, A., Hassan Jawhar, Z., Gupta, J., Nabavi, N., Yu, W., & Ertas, Y. N. (2023). Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environmental Research, 227, 115722. https://doi.org/10.1016/j.envres.2023.115722
Vancouver
Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, et al. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environmental Research. 2023;227:115722. doi:10.1016/j.envres.2023.115722
BibTeX
@article{Almajidi2023,
author = {Almajidi, Yasir Qasim and Kadhim, Mustafa M and Alsaikhan, Fahad and Turki Jalil, Abduladheem and Hassan Sayyid, Nidhal and Alexis Ramírez-Coronel, Andrés and Hassan Jawhar, Zanko and Gupta, Jitendra and Nabavi, Noushin and Yu, Wei and Ertas, Yavuz Nuri},
title = {Doxorubicin-loaded micelles in tumor cell-specific chemotherapy},
journal = {Environmental Research},
year = {2023},
volume = {227},
pages = {115722},
doi = {10.1016/j.envres.2023.115722}
}
EUVIMED